Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics enrols 250 for grass pollen allergy trial

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients.
Allergy Therapeutics enrols 250 for grass pollen allergy trial
Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks

Hay fever vaccine specialist Allergy Therapeutics (LON:AGY) has enrolled 250 patients into a Phase IIb study in the US for a new injectable treatment for grass pollen sufferers.

The dose-setting trial for the vaccine, GrassMATAMPL, will involve 250 patients with headline data expected at the end of the first half of 2016. The results of that should lead on to a US Phase III study.

Allergy said the product design allows for an effective cumulative dose to be attained in up to six weeks, avoiding the continuous administration required by conventional subcutaneous injectable treatments.

For the first time, the dosing study will use two mobile environmental exposure chambers.

Based in Cincinnati and in New Jersey Shore, the chambers are inflatable laboratories that enable subjects to be exposed to a constant concentration of pollen for periods of three hours over four consecutive days. These labs will allow the study to be conducted outside of the grass pollen season.

Tim Higenbottam, Allergy‘s R&D director said the trial was on schedule and would prepare the ground for entry into the high value US market.

“GrassMATAMPL has the potential to become the best in class ultra-short course SCIT [injectable] in the US market”

PhilW.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Related Articles

viagra2.jpg
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
shutterstock_255595165.jpg
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.